Clal Biotechnology (Israel) Top Management

CBI Stock   37.40  0.70  1.84%   
Clal Biotechnology employs about 21 people. The company is managed by 7 executives with a total tenure of roughly 10 years, averaging almost 1.0 years of service per executive, having 3.0 employees per reported executive. Analysis of Clal Biotechnology's management performance can provide insight into the company performance.
Assaf Segal  Executive
Acting Officer
Iris Sadeh  Insider
Accountant
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clal Biotechnology Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Clal Biotechnology Management Team Effectiveness

The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4545) %, meaning that it generated substantial loss on money invested by shareholders. Clal Biotechnology's management efficiency ratios could be used to measure how well Clal Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.

Clal Biotechnology Workforce Comparison

Clal Biotechnology Industries is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 6,095. Clal Biotechnology adds roughly 21.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (1.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.86) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.86.

Clal Biotechnology Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Clal Biotechnology Price Series Summation is a cross summation of Clal Biotechnology price series and its benchmark/peer.

Clal Biotechnology Notable Stakeholders

A Clal Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Clal Biotechnology often face trade-offs trying to please all of them. Clal Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Clal Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Assaf SegalActing OfficerProfile
Iris SadehAccountantProfile
Liat NissanControllerProfile
Shiran ManorCo SecProfile
Etty KligerVP MediWoundProfile
Arnon MDMedical DirectorProfile
Pr MDVP MediWoundProfile

About Clal Biotechnology Management Performance

The success or failure of an entity such as Clal Biotechnology often depends on how effective the management is. Clal Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Clal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Clal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
Please note, the presentation of Clal Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clal Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Clal Biotechnology's management manipulating its earnings.

Clal Biotechnology Workforce Analysis

Traditionally, organizations such as Clal Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Clal Biotechnology within its industry.

Clal Biotechnology Manpower Efficiency

Return on Clal Biotechnology Manpower

Revenue Per Employee3.7M
Revenue Per Executive11M
Net Loss Per Employee4.3M
Net Loss Per Executive12.8M
Working Capital Per Employee9.2M
Working Capital Per Executive27.6M

Complementary Tools for Clal Stock analysis

When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments